Expression of Ceramide-Metabolizing Enzymes in the Heart Adipose Tissue of Cardiovascular Disease Patients

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Jun 10

PMID 37298446

Authors

Olga Gruzdeva

Yulia Dyleva

Ekaterina Belik

Evgenia Uchasova

Anastasia Ponasenko

Sergey Ivanov

Maxim Zinets

Alexander Stasev

Anton Kutikhin

Victoria Markova

Alena Poddubnyak

Evgenia Gorbatovskaya

Elena Fanaskova

Olga Barbarash

Affiliations

Soon will be listed here.

Abstract

Here, we examined the expression of ceramide metabolism enzymes in the subcutaneous adipose tissue (SAT), epicardial adipose tissue (EAT) and perivascular adipose tissue (PVAT) of 30 patients with coronary artery disease (CAD) and 30 patients with valvular heart disease (VHD) by means of quantitative polymerase chain reaction and fluorescent Western blotting. The EAT of patients with CAD showed higher expression of the genes responsible for ceramide biosynthesis (, , , , , , and ) and utilization (, ). PVAT was characterized by higher mRNA levels of , , , , and ceramide utilization enzyme (). In patients with VHD, there was a high , , and expression in the EAT and and expression in the PVAT. Among patients with CAD, the expression of in SAT and EAT, in EAT, in all studied AT, and in EAT, in SAT and EAT, in all studied AT, and in EAT was higher than in those with VHD. Protein levels of ceramide-metabolizing enzymes were consistent with gene expression trends. The obtained results indicate an activation of ceramide synthesis de novo and from sphingomyelin in cardiovascular disease, mainly in EAT, that contributes to the accumulation of ceramides in this location.

Citing Articles

Identification of potential biomarkers for coronary slow flow using untargeted metabolomics.

Chen Y, Liang J, Chen S, Chen B, Guan F, Liu X Metabolomics. 2025; 21(1):23.

PMID: 39920375 DOI: 10.1007/s11306-025-02223-5.

Ceramides-Emerging Biomarkers of Lipotoxicity in Obesity, Diabetes, Cardiovascular Diseases, and Inflammation.

Delcheva G, Stefanova K, Stankova T Diseases. 2024; 12(9).

PMID: 39329864 PMC: 11443555. DOI: 10.3390/diseases12090195.

References

Pan W, Yu J, Shi R, Yan L, Yang T, Li Y . Elevation of ceramide and activation of secretory acid sphingomyelinase in patients with acute coronary syndromes. Coron Artery Dis. 2014; 25(3):230-5. DOI: 10.1097/MCA.0000000000000079. View

Eckel R, Kahn R, Robertson R, Rizza R . Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Diabetes Care. 2006; 29(7):1697-9. DOI: 10.2337/dc06-9911. View

Iacobellis G . Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022; 19(9):593-606. PMC: 8926097. DOI: 10.1038/s41569-022-00679-9. View

Li Y, Talbot C, Chaurasia B . Ceramides in Adipose Tissue. Front Endocrinol (Lausanne). 2020; 11:407. PMC: 7316884. DOI: 10.3389/fendo.2020.00407. View

Mahabadi A, Berg M, Lehmann N, Kalsch H, Bauer M, Kara K . Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall Study. J Am Coll Cardiol. 2013; 61(13):1388-95. DOI: 10.1016/j.jacc.2012.11.062. View

Hogea T, Suciu B, Ivanescu A, Carasca C, Chinezu L, Arbanasi E . Increased Epicardial Adipose Tissue (EAT), Left Coronary Artery Plaque Morphology, and Valvular Atherosclerosis as Risks Factors for Sudden Cardiac Death from a Forensic Perspective. Diagnostics (Basel). 2023; 13(1). PMC: 9818730. DOI: 10.3390/diagnostics13010142. View

Hammerschmidt P, Bruning J . Contribution of specific ceramides to obesity-associated metabolic diseases. Cell Mol Life Sci. 2022; 79(8):395. PMC: 9252958. DOI: 10.1007/s00018-022-04401-3. View

Kim Y, Lee E, Shin K, Kim M, Pewzner-Jung Y, Lee Y . Hepatic triglyceride accumulation via endoplasmic reticulum stress-induced SREBP-1 activation is regulated by ceramide synthases. Exp Mol Med. 2019; 51(11):1-16. PMC: 6825147. DOI: 10.1038/s12276-019-0340-1. View

Goossens G . The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav. 2007; 94(2):206-18. DOI: 10.1016/j.physbeh.2007.10.010. View

10.

Cataldi S, Borrelli A, Ceccarini M, Nakashidze I, Codini M, Belov O . Acid and Neutral Sphingomyelinase Behavior in Radiation-Induced Liver Pyroptosis and in the Protective/Preventive Role of rMnSOD. Int J Mol Sci. 2020; 21(9). PMC: 7247354. DOI: 10.3390/ijms21093281. View

11.

Pavoine C, Pecker F . Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. Cardiovasc Res. 2009; 82(2):175-83. PMC: 2855341. DOI: 10.1093/cvr/cvp030. View

12.

Goldenberg J, Carley A, Ji R, Zhang X, Fasano M, Schulze P . Preservation of Acyl Coenzyme A Attenuates Pathological and Metabolic Cardiac Remodeling Through Selective Lipid Trafficking. Circulation. 2019; 139(24):2765-2777. PMC: 6557671. DOI: 10.1161/CIRCULATIONAHA.119.039610. View

13.

Law B, Liao X, Moore K, Southard A, Roddy P, Ji R . Lipotoxic very-long-chain ceramides cause mitochondrial dysfunction, oxidative stress, and cell death in cardiomyocytes. FASEB J. 2017; 32(3):1403-1416. PMC: 5892719. DOI: 10.1096/fj.201700300R. View

14.

Laviad E, Albee L, Pankova-Kholmyansky I, Epstein S, Park H, Merrill Jr A . Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J Biol Chem. 2008; 283(9):5677-84. DOI: 10.1074/jbc.M707386200. View

15.

Parveen F, Bender D, Law S, Mishra V, Chen C, Ke L . Role of Ceramidases in Sphingolipid Metabolism and Human Diseases. Cells. 2019; 8(12). PMC: 6952831. DOI: 10.3390/cells8121573. View

16.

Bandet C, Tan-Chen S, Bourron O, Le Stunff H, Hajduch E . Sphingolipid Metabolism: New Insight into Ceramide-Induced Lipotoxicity in Muscle Cells. Int J Mol Sci. 2019; 20(3). PMC: 6387241. DOI: 10.3390/ijms20030479. View

17.

Chaurasia B, Talbot C, Summers S . Adipocyte Ceramides-The Nexus of Inflammation and Metabolic Disease. Front Immunol. 2020; 11:576347. PMC: 7538607. DOI: 10.3389/fimmu.2020.576347. View

18.

Park J, Lee S, Shin M, Hwang G . Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction. PLoS One. 2015; 10(8):e0135228. PMC: 4530944. DOI: 10.1371/journal.pone.0135228. View

19.

Gault C, Obeid L, Hannun Y . An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol. 2010; 688:1-23. PMC: 3069696. DOI: 10.1007/978-1-4419-6741-1_1. View

20.

Kolak M, Gertow J, Westerbacka J, Summers S, Liska J, Franco-Cereceda A . Expression of ceramide-metabolising enzymes in subcutaneous and intra-abdominal human adipose tissue. Lipids Health Dis. 2012; 11:115. PMC: 3478226. DOI: 10.1186/1476-511X-11-115. View